866-997-4948(US-Canada Toll Free)

S-1 (Gastric Cancer) - Analysis and Forecasts to 2020

Published By :

GlobalData

Published Date : Oct 2011

Category :

Cancer

No. of Pages : 29 Pages


GlobalDatas pharmaceuticals report, S-1 (Gastric Cancer) - Analysis and Forecasts to 2020 provides S-1 sales estimates for EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Oncology's Disease market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope
  • Therapy area profile including patient population for the EU5 and Japan.
  • Analysis and review of S-1 including historical sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of S-1 including efficacy, safety, pricing, competition and other details which influence its sales potential
  • Detailed sales forecasts for 2002-2020 for S-1 in each of the EU5 and Japan markets

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Contents

1 Table of contents 2
1.1 List of Tables 2
1.2 List of Figures 3

2 Introduction 4
2.1 Gastric Cancer Market 4
2.2 Gastric Cancer Disease 4
2.3 GlobalData Pipeline Report Guidance 6

3 Gastric Cancer Disease: Market Characterization 7
3.1 Gastric Cancer Disease Market 7
3.2 Gastric Cancer Disease Market Forecasts and CAGR 7
3.3 Drivers for the Gastric Cancer Disease Market 7
3.3.1 High Prevalence 8
3.3.2 High Incidence 8
3.3.3 Low Initial Diagnosis Rate 9
3.3.4 High Mortality Rate 9

4 Tumor Node Metastases(TNM) Classification of gastric cancer 10

5 S-1 13

5.1 Introduction 13
5.2 Mechanism of Action 13
5.3 Clinical Studies 13
5.4 Approval History of S-1 14
5.5 Factors Affecting Sales of S-1 14
5.5.1 Gastric Cancer Market in Japan 14
5.5.2 Oral Administration 14
5.5.3 High Efficacy 15
5.5.4 Neo-Adjuvant and Adjuvant Chemotherapy 15
5.5.5 Lack of Presence in the US market 15
5.6 Drug Risk Benefit Score 15
5.6.1 Efficacy 16
5.6.2 Safety 16
5.6.3 Compliance 16
5.6.4 Dosing Convenience 16
5.7 Intensity of Competition 16
5.8 Sales forecast 16
5.8.1 Target patient Pool of S-1 16
5.8.2 Dosing 17
5.8.3 Market Penetration 17
5.8.4 Annual Cost of Therapy 17
5.8.5 Sales Projections of S-1 18

6 Appendix 25
6.1 Abbreviations 25
6.2 Research Methodology 25
6.2.1 Coverage 25
6.2.2 Secondary Research 26
6.2.3 Forecasting 26
6.2.4 Number of Patients Approved to take the Drug 26
6.2.5 Net Penetration of Drug 27
6.2.6 Net Annual Dosing 28
6.2.7 Annual Cost of Therapy 28
6.2.8 Primary Research 28
6.2.9 Expert Panels 28
6.3 Contact Us 28
6.4 Disclaimer 29
6.5 Sources 29

List of Table


Table 1: Gastric Cancer, Incidences and Mortality, 2008-2030 5
Table 2: Gastric Cancer, Global, Market Size Forecast ($bn), 20092020 7
Table 3: Approval History of S-1 14
Table 4: Drug Risk Benefit Score of S-1 15
Table 5: Gastric Cancer, Japan, Estimated Sales for S-1 ($m), 20022020 18
Table 6: Gastric Cancer, The UK, Estimated Sales for S-1 ($m), 20112020 19
Table 7: Gastric Cancer, France, Estimated Sales for S-1 ($m), 20112020 20
Table 8: Gastric Cancer, Germany, Estimated Sales for S-1 ($m), 20112020 21
Table 9: Gastric Cancer, Italy, Estimated Sales for S-1 ($m), 20112020 22
Table 10: Gastric Cancer, Spain, Estimated Sales for S-1 ($m), 20112020 23
Table 11: Gastric Cancer, Global, Estimated Sales for S-1 ($m), 20022020 24

List of Chart


Figure 1: Percentage Distribution of Top 20 Cancers 4
Figure 2: Fatality = [(%Distribution of Incidence) (% Distribution Mortality )] of Top 20 Cancers 5
Figure 3: Per Capita Cigarette Consumption , The US, 1976-2006 6
Figure 4: Gastric Cancer, Global, Market Size Forecast ($bn), 20092020 7
Figure 5: Oncology, Global, Incidence (in millions), 2008-2030 8
Figure 6: Gastric Cancer, Global, Incidence (in millions), 2008-2030 8
Figure 7: Broad Classification of Gastric Cancer in the US and EU-5 10
Figure 8: Broad Classification of Gastric Cancer in Japan 10
Figure 9: Detailed TNM Classification 11
Figure 10: Classification of Gastric Cancer in the US and EU-5 12
Figure 11: Classification of Gastric Cancer in Japan 12
Figure 12: Phase III results, S-1+Cisplatin 14
Figure 13: Drug Model Diagram of S-1 17
Figure 14: Gastric Cancer, Japan, Estimated Sales for S-1 ($m), 20022020 18
Figure 15: Gastric Cancer, The UK, Estimated Sales for S-1 ($m), 20112020 19
Figure 16: Gastric Cancer, France, Estimated Sales for S-1 ($m), 20022020 20
Figure 17: Gastric Cancer, Germany, Estimated Sales for S-1 ($m), 20112020 21
Figure 18: Gastric Cancer, Italy, Estimated Sales for S-1 ($m), 20112020 22
Figure 19: Gastric Cancer, Spain, Estimated Sales for S-1 ($m), 20112020 23
Figure 20: Gastric Cancer, Global, Estimated Sales for S-1 ($m), 20022020 24
Figure 21: GlobalData Methodology 25
Figure 22: Drug Model Diagram 27
Figure 23: Patients Approved for the Drug 27

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *